Search Results

Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher’s prior FDA-approved ketamine experience Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist’s real-world treatment foundation KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise

Brings extensive experience in patient care, dermatologic research and commercialization

Ad hoc announcement pursuant to Art. 53 LR • The next phase of the greenfield project in Sisslerfeld (Eiken, Switzerland) will be implemented as part of a strategic collaboration. • Total investment amounts to more than CHF 500 million. • Start of commercial production at the new site is expected in 2030.

Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.